EFG International AG Takes Position in IQVIA Holdings Inc. $IQV

Posted by Brenda Bartman on Aug 28th, 2026

EFG International AG purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,539 shares of the medical research company’s stock, valued at approximately $491,000.

Several other institutional investors and hedge funds also recently bought and sold shares of IQV. Ascentis Independent Advisors bought a new position in IQVIA during the 1st quarter valued at about $25,000. Financial Freedom LLC bought a new stake in IQVIA in the first quarter worth about $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA during the fourth quarter valued at approximately $27,000. Gilpin Wealth Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $27,000. Finally, Compass Financial Management LLC purchased a new stake in shares of IQVIA in the second quarter worth approximately $27,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQV opened at $262.18 on Friday. The company has a market capitalization of $43.15 billion, a price-to-earnings ratio of 32.53, a PEG ratio of 2.23 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $265.25. The business’s fifty day simple moving average is $220.29 and its 200-day simple moving average is $189.12.

IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period in the prior year, the firm earned $2.81 earnings per share. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a stock buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Robert W. Baird upped their price objective on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. BMO Capital Markets raised their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. William Blair raised shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Royal Bank Of Canada upped their target price on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $241.88.

Check Out Our Latest Research Report on IQV

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 over the last quarter. 1.70% of the stock is currently owned by company insiders.

IQVIA Company Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.